Behind the prescription outflow: challenges and opportunities for hospital side stores
A few days ago, the Heilongjiang Provincial Drug Administration issued the "Implementation Plan for the Inspection of the Business Quality of Drug Retail Enterprises around Hospitals" (hereinafter referred to as the "Plan"), requiring drug regulatory authorities around the region to organize a one-month supervision and inspection of drug retail enterprises around hospitals under their jurisdiction, especially the tertiary hospitals. In this regard, the drug retail enterprises around hospitals (hereinafter referred to as "hospital-side stores"), which have been extremely hot in recent years, have been brought to the attention of the industry again. At present, although there are various problems in the hospital side stores, but with the promotion of prescription outflow and the development of the out-of-hospital market, its future is still promising. For pharmaceutical companies, they must do a good job of targeted marketing in order to seize the first opportunity in the hospital side store market.
Looking for chemical products? Let suppliers reach out to you!
2026-07-18
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Biocytogen announces the launch of the 'Nano 100 Project' to develop fully human therapeutic nanobodies against 100+ targets
-
Wantai Biotech 20-valent pneumonia vaccine started clinical trials, how far is domestic substitution?
-
Yiming Cell 'Suspension 293XS Cell Bank' completed DMF filing with the US FDA
-
The phase III clinical study of Junshi Biologics in combination with teripulimab in the treatment of advanced triple-negative breast cancer reached the primary endpoint
-
The next bombshell: 'PD-1 + ADC', Kelun, Hengrui are going to win numbness?
-
L-Rotator Biotech completed its pre-A financing and continued to increase its investment in the CGT field
-
Hainan to promote drug import facilitation
-
Enable the 'export of EU APIcertification documents' and 'pharmaceutical export salescertificate' electronic proof
-
China to focus on building quality and efficient TCM service system in next five years
Recommend Reading
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
Japan Begins Construction of the World’s Largest Commercial Liquid Hydrogen Receiving Terminal
-
Bivalirudin: Medical Uses, Properties, and Safety
-
Increased Supply Causes Oscillating Decline in Isooctanol Prices This Week
-
This Week's Isopropyl Alcohol Market Prices Decrease (8.11-8.15) in China
-
This Week, DMF Market Prices Remain Stable in China (8.8-8.15)